Hiroshi Nomoto

15.9k total citations
175 papers, 3.3k citations indexed

About

Hiroshi Nomoto is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Hiroshi Nomoto has authored 175 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Molecular Biology, 65 papers in Endocrinology, Diabetes and Metabolism and 36 papers in Surgery. Recurrent topics in Hiroshi Nomoto's work include Diabetes Treatment and Management (42 papers), Metabolism, Diabetes, and Cancer (33 papers) and Nerve injury and regeneration (30 papers). Hiroshi Nomoto is often cited by papers focused on Diabetes Treatment and Management (42 papers), Metabolism, Diabetes, and Cancer (33 papers) and Nerve injury and regeneration (30 papers). Hiroshi Nomoto collaborates with scholars based in Japan, United States and United Kingdom. Hiroshi Nomoto's co-authors include Shoei Furukawa, Hidefumi Fukumitsu, Atsumi Nitta, Yoshiko Furukawa, Hideaki Miyoshi, Tatsuya Atsumi, Akinobu Nakamura, Yasuo Inoue, Satoshi Mishima and Noriko Hattori and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and The Journal of Cell Biology.

In The Last Decade

Hiroshi Nomoto

161 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroshi Nomoto Japan 33 1.3k 635 634 450 371 175 3.3k
Kazuto Yamazaki Japan 35 2.0k 1.5× 862 1.4× 612 1.0× 399 0.9× 85 0.2× 123 4.3k
Koji Aoyama Japan 36 1.6k 1.2× 738 1.2× 138 0.2× 843 1.9× 118 0.3× 110 4.8k
Gu Seob Roh South Korea 37 1.7k 1.3× 411 0.6× 372 0.6× 356 0.8× 111 0.3× 149 4.1k
Francisco J. Romero Spain 37 1.3k 1.0× 541 0.9× 204 0.3× 128 0.3× 231 0.6× 120 4.4k
Subbiah Pugazhenthi United States 32 1.8k 1.4× 422 0.7× 596 0.9× 548 1.2× 100 0.3× 82 4.0k
Daniel A. Linseman United States 37 2.4k 1.9× 692 1.1× 171 0.3× 184 0.4× 179 0.5× 87 4.3k
Tiina Suuronen Finland 34 2.6k 2.0× 390 0.6× 161 0.3× 196 0.4× 147 0.4× 59 5.2k
Paul Morley Canada 38 2.4k 1.9× 1.7k 2.6× 280 0.4× 217 0.5× 345 0.9× 138 5.1k
Mei Xu United States 43 2.3k 1.8× 1.4k 2.3× 435 0.7× 439 1.0× 141 0.4× 133 5.3k
José A. Pariente Spain 43 1.7k 1.3× 567 0.9× 305 0.5× 464 1.0× 40 0.1× 151 5.3k

Countries citing papers authored by Hiroshi Nomoto

Since Specialization
Citations

This map shows the geographic impact of Hiroshi Nomoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Nomoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Nomoto more than expected).

Fields of papers citing papers by Hiroshi Nomoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Nomoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Nomoto. The network helps show where Hiroshi Nomoto may publish in the future.

Co-authorship network of co-authors of Hiroshi Nomoto

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Nomoto. A scholar is included among the top collaborators of Hiroshi Nomoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Nomoto. Hiroshi Nomoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shinozaki, Yuichi, Miki Ito, Hiroyoshi Kurihara, et al.. (2025). The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study. Pharmaceuticals. 18(1). 129–129. 3 indexed citations
2.
Hashiguchi, Saori, et al.. (2025). Hypoglycemic coma owing to sensor device dysfunction after an automatic smartphone operating system update. Therapeutic Advances in Endocrinology and Metabolism. 16. 2465769830–2465769830.
3.
Oe, Yuki, Hiroshi Nomoto, Kyu Yong Cho, et al.. (2025). Efficacy and safety of tirzepatide in subjects with type 2 diabetes and chronic kidney disease: a prospective, two-arm observational study. Therapeutic Advances in Endocrinology and Metabolism. 16. 2465747496–2465747496.
4.
Nomoto, Hiroshi, Yuki Yamauchi, Kazuno Omori, et al.. (2024). Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease. Diabetes & Metabolism Journal. 48(3). 473–481. 5 indexed citations
5.
6.
Kameda, Hiraku, Akinobu Nakamura, Hiroshi Nomoto, et al.. (2023). Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas. Pituitary. 26(5). 597–610. 1 indexed citations
7.
8.
9.
10.
Nomoto, Hiroshi, Yuka Takahashi, Hiroki Yokoyama, et al.. (2023). Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis. Pharmaceutics. 15(8). 2163–2163. 9 indexed citations
11.
12.
13.
Kameda, Hiraku, Hiroshi Nomoto, Kyu Yong Cho, et al.. (2021). Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study. Journal of Diabetes Investigation. 12(11). 1978–1982. 6 indexed citations
14.
Nakamura, Akinobu, Hiroshi Nomoto, Hiraku Kameda, et al.. (2021). Impact of low-starch high-fiber pasta on postprandial blood glucose. Nutrition Metabolism and Cardiovascular Diseases. 32(2). 487–493. 7 indexed citations
15.
Miya, Aika, Akinobu Nakamura, Kyu Yong Cho, et al.. (2020). Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin. Journal of Diabetes Investigation. 12(8). 1395–1399. 1 indexed citations
16.
Nakamura, Akinobu, Hiroshi Nomoto, Hiraku Kameda, et al.. (2020). Combination of alcohol and glucose consumption as a risk to induce reactive hypoglycemia. Journal of Diabetes Investigation. 12(4). 651–657. 13 indexed citations
17.
Nomoto, Hiroshi, Akinobu Nakamura, Kyu Yong Cho, et al.. (2020). Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes. Journal of Diabetes Investigation. 12(2). 176–183. 10 indexed citations
18.
Montemurro, Chiara, Hiroshi Nomoto, Vishal S. Parekh, et al.. (2019). IAPP toxicity activates HIF1α/PFKFB3 signaling delaying β-cell loss at the expense of β-cell function. Nature Communications. 10(1). 2679–2679. 64 indexed citations
19.
Nakamura, Akinobu, Kohei Yamamoto, Hiroshi Nomoto, et al.. (2018). Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial. Journal of Diabetes Investigation. 10(3). 699–705. 29 indexed citations
20.
Takahashi, Kiyohiko, Kyu Yong Cho, Akinobu Nakamura, et al.. (2018). Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation. 10(2). 429–438. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazuto Yamazaki Breakdown of academic impact, for papers by Koji Aoyama Breakdown of academic impact, for papers by Gu Seob Roh Breakdown of academic impact, for papers by Francisco J. Romero Breakdown of academic impact, for papers by Subbiah Pugazhenthi Breakdown of academic impact, for papers by Daniel A. Linseman Breakdown of academic impact, for papers by Tiina Suuronen Breakdown of academic impact, for papers by Paul Morley Breakdown of academic impact, for papers by Mei Xu Breakdown of academic impact, for papers by José A. Pariente
Rankless by CCL
2026